Hostname: page-component-745bb68f8f-5r2nc Total loading time: 0 Render date: 2025-01-10T13:17:10.215Z Has data issue: false hasContentIssue false
  • English
  • Français

Aripriprazole induced severe oculogyric dystonia treated with electroconvulsive therapy(ECT)

Published online by Cambridge University Press:  19 July 2023

K. Bhat Shah ,
T. S. Bhat ,
J. S. Pawar  and
N. Pande
K. Bhat Shah*
Affiliation:
Ophthalmology, JMF’S ACPM Medical College Dhule
T. S. Bhat
Affiliation:
Psychiatry, JMF’S ACPM Medical College
J. S. Pawar
Affiliation:
Psychiatry, Shri Bhausaheb Hire Medical College, Dhule
N. Pande
Affiliation:
Psychiatry, Orange City Hospital, Nagpur, India
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Aripiprazole is the third generation Antipsychotic, and Dopamine serotonin system stabiliser.It is partial agonist at D2 and 5 HT1 A and antagonist at 5 HT2.Most commonly seen adverse effects are Akathesia, fatugue,insomnia and headache the major advanatage is less propensity for extrapyramidal side effects and lmetabolic side eefects.

Objectives

To report a case of Schizophrenia treated with Aripiprazole 15mg/day developiing occular gyric crisis which was tratment resistant.

Methods

We administered Electroconvulsvive therapy, bidirectional brief pulse constant current 8 ECTS, under General anesthesia with medical fitness .

Results

Patient Showed complete resolution of Dystonia after second ECTs and Showed improvment in Pyschosis Parameterd. Assessment using Naranjo Protocol made.

Conclusions

Electroconvulsive therapy therapy is viable alternative to manage Dystonia when medical treatment fails

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1009
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.